Canopy Growth (CGC)
NASDAQ:CGC
Earnings Data
Report Date
May 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-0.07Last Year’s EPS
-1.03Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed clear progress across multiple fronts: a materially stronger balance sheet (post-quarter recap), meaningful cost savings, sequential stabilization and growth internationally, and strong momentum in key product lines (medical, adult-use pre-rolls/vapes, and Storz & Bickel VEAZY). At the same time, the company faces margin pressures (cannabis and S&B gross margins down ~3ppt YoY), a still-negative adjusted EBITDA (narrowed to −$3M), a negative free cash flow outflow (−$19M) and near-term policy and tariff headwinds (veterans reimbursement reduction and tariffs). Overall, positives (liquidity, cost savings, revenue growth in core channels, narrowing EBITDA loss and clear path to FY27 profitability) outweigh the lowlights, though material risks remain in margins and policy that management is actively addressing.Company Guidance
Stronger Balance Sheet and Liquidity
Ended Q3 with $371M in cash and cash equivalents and a net cash position of $146M; completed a post-quarter USD 150M recapitalization that improved near-term liquidity and extended debt maturities to 2031 (company cited roughly $425M post-recap in Q&A).
Narrowest Adjusted EBITDA Loss to Date
Adjusted EBITDA loss narrowed to $3M (the company's slimmest adjusted EBITDA loss), driven by cost discipline and operational improvements, and management targets positive adjusted EBITDA during fiscal 2027.
Material Cost Savings Delivered
Identified and captured $29M of annualized cost savings, with SG&A (ex-acquisition/divestiture/other) down 12% year-over-year.
Canada Medical Revenue Growth
Canada medical net revenue grew 15% year-over-year to $23M, marking the sixth consecutive quarter of growth driven by insured patient registrations, larger order sizes and improved service levels.
Canada Adult-Use Revenue Growth
Canada adult-use net revenue increased 8% year-over-year to $23M, supported by strength in infused pre-rolls and new All-In-One vapes and improved retail execution.
International and Storz & Bickel Momentum
International cannabis sales rose 22% sequentially as the business stabilized; Storz & Bickel net revenue increased 45% sequentially to $23M, with Black Friday online sales up 16% year-over-year and the first full quarter sales of the VEAZY device.
Free Cash Flow Trajectory Improving
Free cash flow was an outflow of $19M in Q3, improved from an outflow of $28M in the same period last year (a $9M year-over-year improvement driven by lower cash interest and working capital movements).
CGC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CGC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 06, 2026 | $1.08 | $1.10 | +1.85% |
Nov 07, 2025 | $1.09 | $1.17 | +7.34% |
Aug 08, 2025 | $1.05 | $1.25 | +19.05% |
May 30, 2025 | $1.71 | $1.32 | -22.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Canopy Growth (CGC) report earnings?
Canopy Growth (CGC) is schdueled to report earning on May 29, 2026, Before Open (Confirmed).
What is Canopy Growth (CGC) earnings time?
Canopy Growth (CGC) earnings time is at May 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CGC EPS forecast?
CGC EPS forecast for the fiscal quarter 2026 (Q4) is -0.07.
